Health Care·Biotechnology·$161.9B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.78 | N/A | +13.37% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $0.78 | N/A | +13.37% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Overall, management conveyed a sense of cautious optimism regarding their future prospects. They emphasized the importance of their product pipeline.
Management highlighted the strong performance in their key therapeutic areas.
They expressed confidence in their pipeline and ongoing research efforts.
Gilead Sciences reported a better-than-expected EPS, indicating strong performance in certain areas. However, the lack of revenue data and guidance leaves some uncertainty for investors. The stock reaction is not available, which may reflect the cautious sentiment in the market.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
BOSTON SCIENTIFIC CO
Oct 19, 2009